Status:
UNKNOWN
Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma
Lead Sponsor:
Fudan University
Conditions:
Hepatocellular Carcinoma
Unresectable
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Songyou Granule is a mixture of 6 herbs. Vitro and vivo studies showed that Songyou Granule can inhibit HCC cells grow, and HCC metastasis. Hypothesis of this study is that TACE plus Songyou Granule w...
Detailed Description
Primary outcome Measures: To evaluate the effect of TACE plus Songyou Granule or TACE plus placebo on TTP Secondary Outcome Measures: * Overall survival (OS) * Progression Free Survival (PFS) * The...
Eligibility Criteria
Inclusion
- Adults patients (≥ 18 years of age) with a diagnosis of HCC which is not amenable to surgical resection or local ablative therapy
- Histological confirmed HCC or clinical/laboratory diagnosis of HCC or nodules larger than 2 cm with typical vascular features or AFP \> 200
- Patient must have quantifiable disease limited to the liver
- Patients must have at least one tumor lesion that meets both of the following criteria:
- The lesion can be accurately measured in at least one dimension according to RECIST criteria
- The lesion has not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation.
- ECOG performance status (PS) \<2
- No prior targeted antiangiogenic therapy. Metronomic chemotherapies are allowed. At least 4 weeks since prior systemic chemotherapy
- No significant baseline liver dysfunction. Cirrhotic status of Child-Pugh class A or B
- No significant renal impairment (creatinine clearance \< 30 mL/minute) or patients on dialysis
- The following laboratory parameters:
- Platelet count ≥ 50,000/µL
- Hemoglobin ≥ 8.5 g/dL
- Total bilirubin ≤ 2 mg/dL
- ASL and AST ≤ 5 x upper limit of normal
- Serum creatinine ≤ 1.5 x upper limit of normal
- INR ≤ 1.5 or a PTT within normal limits
- Ability to understand the protocol and to agree to and sign a written informed consent document
Exclusion
- Previous or concurrent cancer that is distinct in primary site or histology from HCC except cervical carcinoma in situ, treated basal-cell carcinoma of the skin, superficial bladder tumors (Ta, Tis \& T1), and any cancer curatively treated \> 3 years prior to entry is permitted
- Renal failure requiring hemo- or peritoneal dialysis
- Child-Pugh C hepatic impairment
- Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
- Known central nervous system tumors including metastatic brain disease
- History of organ allograft
- Substance abuse (current), psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- Known or suspected allergy to the investigational agents or any agent given in association with this trial.
- Patients unable to swallow oral medications.
- Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of the study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00805896
Start Date
December 1 2008
End Date
December 1 2010
Last Update
December 31 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200032
2
Liver Cancer Institute and Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200032